title: [Mechanisms for reversal of pulmonary hypertension by rapamycin in rats].
abstract: OBJECTIVE
  To investigate the effects of rapamycin (RAP) on pulmonary hypertension (PH) in rats, and to provide new insights into medication selection for the clinical treatment of PH.
  
  
  METHODS
  Fifty male Sprague-Dawley rats were randomly divided into blank control, PH model, solvent control, RAP 1, and RAP 2 groups. A rat model of PH was induced by left pneumonectomy (PE) and monocrotaline (MCT). At 5 days after PH model establishment, the solvent control group and the RAP 1 group received an intramuscular injection of solvent and RAP, respectively. At 35 days after PH model establishment, the RAP 2 group received an intramuscular injection of RAP. The mean pulmonary artery pressure (mPAP) and the right ventricle/left ventricle plus septum weight ratio (RV/LV+S) were measured in each group. Histopathological changes in the right lung were evaluated by hematoxylin-eosin (HE) staining. The relative expression of alpha-smooth muscle actin (α-SMA) and smooth muscle protein 22-alpha (SM22α) in each group was determined using real-time PCR.
  
  
  RESULTS
  At 35 days after surgery, the PH model and the solvent control groups had significantly higher mPAP and RV/LV+S than the blank control group, while the RAP 1 and the RAP 2 groups had significantly lower mPAP than the solvent control group (P<0.05). The RV/LV+S in the RAP 1 group was significantly lower than that in the solvent control group (P<0.05); however, there was no significant difference in RV/LV+S between the RAP 2 and the solvent control groups (P>0.05). HE staining in the right lung showed the substantially thickened pulmonary artery wall and narrowed arterial lumen in the PH model and the solvent control groups compared with the blank control group. Different degrees of reversal of the pulmonary artery wall thickening were observed after RAP administration. The results of real-time PCR revealed that the relative expression of α-SMA and SM22α in the PH model and the solvent control groups was significantly lower than in the blank control group, while the relative expression of α-SMA and SM22α in the RAP 1 and the RAP 2 groups was significantly higher than in the solvent control group (P<0.05).
  
  
  CONCLUSIONS
  RAP can reverse the increase in pulmonary artery pressure and the right ventricular hypertrophy probably by regulation of the phenotypic conversion of vascular smooth muscle cells.
authors.affiliation: Department of Pediatric Cardiology, West China Second University Hospital, Sichuan University, Chengdu 610041, China. myuxuan@163.net.
authors.forename: Li
authors.initials: L
authors.lastname: Yu
authors.forename: Zhi-Yu
authors.initials: ZY
authors.lastname: Fan
authors.forename: Liang
authors.initials: L
authors.lastname: Xie
authors.forename: Chun-Yu
authors.initials: CY
authors.lastname: Li
authors.forename: Chao-Yi
authors.initials: CY
authors.lastname: Qin
authors.forename: Li-Jun
authors.initials: LJ
authors.lastname: Liu
authors.forename: Han-Min
authors.initials: HM
authors.lastname: Liu
mesh_terms: D000199:Actins / Q000235:genetics; D000818:Animals; D006439:Hemodynamics; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D017380:Hypertrophy, Right Ventricular / Q000209:etiology; D008297:Male; D008840:Microfilament Proteins / Q000235:genetics; D009124:Muscle Proteins / Q000235:genetics; D011651:Pulmonary Artery / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D000199:Actins; D008840:Microfilament Proteins; D009124:Muscle Proteins; D012333:RNA, Messenger; D020123:Sirolimus; C498862:Acta2 protein, rat; C051615:transgelin